207 related articles for article (PubMed ID: 28409399)
1. Pro-apoptotic signaling induced by Retinoic acid and dsRNA is under the control of Interferon Regulatory Factor-3 in breast cancer cells.
Bernardo AR; Cosgaya JM; Aranda A; Jiménez-Lara AM
Apoptosis; 2017 Jul; 22(7):920-932. PubMed ID: 28409399
[TBL] [Abstract][Full Text] [Related]
2. Synergy between RA and TLR3 promotes type I IFN-dependent apoptosis through upregulation of TRAIL pathway in breast cancer cells.
Bernardo AR; Cosgaya JM; Aranda A; Jiménez-Lara AM
Cell Death Dis; 2013 Jan; 4(1):e479. PubMed ID: 23370279
[TBL] [Abstract][Full Text] [Related]
3. Innate immune response to double-stranded RNA in biliary epithelial cells is associated with the pathogenesis of biliary atresia.
Harada K; Sato Y; Itatsu K; Isse K; Ikeda H; Yasoshima M; Zen Y; Matsui A; Nakanuma Y
Hepatology; 2007 Oct; 46(4):1146-54. PubMed ID: 17661372
[TBL] [Abstract][Full Text] [Related]
4. Enhanced extrinsic apoptosis of therapy-induced senescent cancer cells using a death receptor 5 (DR5) selective agonist.
Soto-Gamez A; Wang Y; Zhou X; Seras L; Quax W; Demaria M
Cancer Lett; 2022 Jan; 525():67-75. PubMed ID: 34728311
[TBL] [Abstract][Full Text] [Related]
5. Hepatocyte expression of TRAIL pathway regulators correlates with histopathological and clinical parameters in chronic HCV infection.
Brost S; Zimmermann A; Koschny R; Sykora J; Stremmel W; Schirmacher P; Walczak H; Ganten TM
Pathol Res Pract; 2014 Feb; 210(2):83-91. PubMed ID: 24268735
[TBL] [Abstract][Full Text] [Related]
6. Notch inhibition restores TRAIL-mediated apoptosis via AP1-dependent upregulation of DR4 and DR5 TRAIL receptors in MDA-MB-231 breast cancer cells.
Portanova P; Notaro A; Pellerito O; Sabella S; Giuliano M; Calvaruso G
Int J Oncol; 2013 Jul; 43(1):121-30. PubMed ID: 23686163
[TBL] [Abstract][Full Text] [Related]
7. Transfected poly(I:C) activates different dsRNA receptors, leading to apoptosis or immunoadjuvant response in androgen-independent prostate cancer cells.
Palchetti S; Starace D; De Cesaris P; Filippini A; Ziparo E; Riccioli A
J Biol Chem; 2015 Feb; 290(9):5470-83. PubMed ID: 25568326
[TBL] [Abstract][Full Text] [Related]
8. IPS-1 differentially induces TRAIL, BCL2, BIRC3 and PRKCE in type I interferons-dependent and -independent anticancer activity.
Kumar S; Ingle H; Mishra S; Mahla RS; Kumar A; Kawai T; Akira S; Takaoka A; Raut AA; Kumar H
Cell Death Dis; 2015 May; 6(5):e1758. PubMed ID: 25950488
[TBL] [Abstract][Full Text] [Related]
9. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression.
Eggert A; Grotzer MA; Zuzak TJ; Wiewrodt BR; Ho R; Ikegaki N; Brodeur GM
Cancer Res; 2001 Feb; 61(4):1314-9. PubMed ID: 11245427
[TBL] [Abstract][Full Text] [Related]
10. High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2.
Chamuleau ME; Ossenkoppele GJ; van Rhenen A; van Dreunen L; Jirka SM; Zevenbergen A; Schuurhuis GJ; van de Loosdrecht AA
Leuk Res; 2011 Jun; 35(6):741-9. PubMed ID: 21281967
[TBL] [Abstract][Full Text] [Related]
11. Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism.
Ortiz-Ferrón G; Yerbes R; Eramo A; López-Pérez AI; De Maria R; López-Rivas A
Cell Res; 2008 Jun; 18(6):664-76. PubMed ID: 18458681
[TBL] [Abstract][Full Text] [Related]
12. Role of antiapoptotic proteins in tumor necrosis factor-related apoptosis-inducing ligand and cisplatin-augmented apoptosis.
Kim JH; Ajaz M; Lokshin A; Lee YJ
Clin Cancer Res; 2003 Aug; 9(8):3134-41. PubMed ID: 12912965
[TBL] [Abstract][Full Text] [Related]
13. Control of FoxO4 Activity and Cell Survival by TRIM22 Directs TLR3-Stimulated Cells Toward IFN Type I Gene Induction or Apoptosis.
Oteiza A; Mechti N
J Interferon Cytokine Res; 2015 Nov; 35(11):859-74. PubMed ID: 26237181
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of preventive and therapeutic activity of novel non-steroidal anti-inflammatory drug, CG100649, in colon cancer: Increased expression of TNF-related apoptosis-inducing ligand receptors enhance the apoptotic response to combination treatment with TRAIL.
Woo JK; Kang JH; Jang YS; Ro S; Cho JM; Kim HM; Lee SJ; Oh SH
Oncol Rep; 2015 Apr; 33(4):1947-55. PubMed ID: 25672292
[TBL] [Abstract][Full Text] [Related]
15. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes.
Leverkus M; Neumann M; Mengling T; Rauch CT; Bröcker EB; Krammer PH; Walczak H
Cancer Res; 2000 Feb; 60(3):553-9. PubMed ID: 10676636
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) decoy receptor TRAIL-R3 is up-regulated by p53 in breast tumor cells through a mechanism involving an intronic p53-binding site.
Ruiz de Almodóvar C; Ruiz-Ruiz C; Rodríguez A; Ortiz-Ferrón G; Redondo JM; López-Rivas A
J Biol Chem; 2004 Feb; 279(6):4093-101. PubMed ID: 14623878
[TBL] [Abstract][Full Text] [Related]
17. The TRAIL-receptor-1: TRAIL-receptor-3 and -4 ratio is a predictor for TRAIL sensitivity of cancer cells.
Büneker C; Mohr A; Zwacka RM
Oncol Rep; 2009 May; 21(5):1289-95. PubMed ID: 19360306
[TBL] [Abstract][Full Text] [Related]
18. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
[TBL] [Abstract][Full Text] [Related]
19. Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptor expression in human neutrophils.
Kamohara H; Matsuyama W; Shimozato O; Abe K; Galligan C; Hashimoto S; Matsushima K; Yoshimura T
Immunology; 2004 Feb; 111(2):186-94. PubMed ID: 15027904
[TBL] [Abstract][Full Text] [Related]
20. Signal regulatory protein alpha negatively regulates both TLR3 and cytoplasmic pathways in type I interferon induction.
Dong LW; Kong XN; Yan HX; Yu LX; Chen L; Yang W; Liu Q; Huang DD; Wu MC; Wang HY
Mol Immunol; 2008 Jun; 45(11):3025-35. PubMed ID: 18471880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
